The healthcare data firm raised full-year guidance after Q2 organic revenue growth tripled year-over-year to 6%.
IQVIA Holdings Inc. reported Q2 2026 organic revenue growth of 6%, up from 2% in the prior year, driven by stronger demand in R&D and commercial solutions. The acceleration reflects improved market conditions and higher win rates, particularly in the Emerging Biopharma segment, which now accounts for 70% of global clinical trial starts.
The company cited a 45% increase in new drug launches in H1 2026 and a strategic shift among large pharma toward outsourcing commercialization. Operational productivity gains expanded margins by 90 basis points, offsetting foreign exchange and pass-through cost pressures.
Full-year 2026 guidance was raised by 100 basis points for organic revenue growth, with increased contributions from M&A. AI-enabled capabilities were highlighted as a key differentiator in securing complex Phase III awards.